UNSPSC 51313508: Etolotifen

This classification denotes a histamine-1 receptor antagonist with the molecular formula C24H29NO4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier U64HJ4AK57, chemically known as 4,9-dihydro-4-(1-(2-(-2(2-hydroxyethoxy)ethoxy)ethyl)-4-piperidylidene)-10h-ben-zo(4,5)cyclohepta(1,2-b)thiophen-10-one. but generally known as etolotifen, which bears US NIH Compound Identifier 208944. European Medicines Agency schedules Etolotifen in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07328MIG.

UNSPSC 51313508 Etolotifen is a Commodity code that does not match the work actually being solicited under it in recent state and local procurement activity. The three most recent opportunities posted under this code involve naloxone procurement, direct-to-manufacturer pharmacy programs, and generic multi-source pharmaceutical distribution — none of which are etolotifen-specific products or services. The mismatch suggests either a data-tagging error in the source records or that etolotifen does not drive meaningful procurement volume in state and local markets at present.

The issuing bodies pursuing pharmaceutical-related work under this code include county health departments (Seminole County, Florida), state health and human services agencies (Texas Health and Human Services Commission), and cooperative purchasing alliances serving multiple states (Minnesota Multistate Cooperative Purchasing Alliance, with Oregon participation noted). Geographic activity appears concentrated in Florida, Texas, and the Upper Midwest, though the MMCAP procurement serves a broader multi-state membership. Representative recent opportunities include Seminole County's IFB for 1,900 units of naloxone annually with quarterly deliveries (due July 26, 2023), Texas HHS's RFI on direct-to-manufacturer prescription programs (response due April 3, 2026), and MMCAP's RFP for generic multi-source pharmaceuticals and OTC products distributed through authorized wholesalers, with proposals due March 26, 2026 and contract effectiveness July 1, 2026. The code shows active pharmaceutical procurement across multiple issuing-body types, but the nominal commodity (etolotifen) does not appear in any posted solicitation.